Modified Vaccinia Ankara (MVA) Vaccine Study

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Nasopharyngeal NeoplasmsEpstein-Barr Virus Infections
Interventions
DRUG

MVA Vaccine

The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT01256853 - Modified Vaccinia Ankara (MVA) Vaccine Study | Biotech Hunter | Biotech Hunter